US FDA approves KalVista Pharma's swelling disorder drug

(Reuters) -KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary swelling disorder, sending its shares up 33.3% in premarket trading. The regulator's greenlight comes after it extended the review of the drug, Ekterly, due to heavy workload and limited resources. With the approval, Ekterly becomes the first on-demand oral